Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours

被引：40
作者：
Wumkes, M. L. [1 ]
van der Velden, A. M. T. [1 ]
Los, M. [2 ]
Leys, M. B. L. [3 ]
Beeker, A. [4 ]
Nijziel, M. R. [5 ]
van der Velden, A. W. G. [6 ]
Westerman, M. [7 ]
Meerveld-Eggink, A. [2 ]
Rimmelzwaan, G. F. [8 ]
Rijkers, G. T. [9 ]
Biesma, D. H. [2 ,10 ]
机构：
[1] Tergooi Hilversum Blaricum, Dept Internal Med, NL-1201 DA Hilversum, Netherlands
[2] St Antonius Hosp Nieuwegein, Dept Internal Med, NL-3430 EM Nieuwegein, Netherlands
[3] Maasstad Hosp Rotterdam, Dept Internal Med, NL-3007 AC Rotterdam, Netherlands
[4] Spaarne Hosp Hoofddorp, Dept Internal Med, NL-2130 AT Hoofddorp, Netherlands
[5] Maxima Med Ctr Eindhoven, Dept Internal Med, NL-5600 PD Eindhoven, Netherlands
[6] Martini Hosp Groningen, Dept Internal Med, NL-9700 RM Groningen, Netherlands
[7] Med Ctr Alkmaar, Dept Internal Med, NL-1800 AM Alkmaar, Netherlands
[8] Erasmus MC, Dept Virol, NL-3000 CA Rotterdam, Netherlands
[9] St Antonius Hosp Nieuwegein, Dept Med Microbiol & Immunol, NL-3430 EM Nieuwegein, Netherlands
[10] Univ Med Ctr Utrecht, Dept Internal Med, NL-3508 GA Utrecht, Netherlands
来源：
VACCINE | 2013年 / 31卷 / 52期
关键词：
Chemotherapy; Influenza virus vaccination; Solid tumours; IMMUNIZATION; CANCER; RECOMMENDATIONS; IMMUNOGENICITY;
D O I：
10.1016/j.vaccine.2013.10.053
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Background: Higher rates of hospitalization and mortality are described in oncology patients with influenza virus infection compared to the general population. Yearly influenza vaccination is recommended for patients treated with chemotherapy. The optimal moment to administer the vaccine during a treatment cycle has not been studied extensively. Patients and methods: During the influenza season 2011-2012 we conducted a multicenter randomized controlled trial (OFLUVAC, NTR2858, no sponsoring) in the Netherlands. Patients receiving adjuvant chemotherapy for breast or colorectal cancer were randomized between early (day 5 after chemotherapy) and late (day 16 after chemotherapy) vaccination with the influenza virus vaccine (Influvac (R) 2011/2012-Vaxigrip (R) 2011/2012). Influenza virus-specific antibody titres were determined before, 3 and 12 weeks after vaccination by haemagglutination inhibition. Results: Thirty-eight breast cancer patients (early = 21; late = 17) and 18 colorectal cancer patients (early = 8; late = 10) were analyzed. In breast cancer patients overall serologic responses were adequate. A statistically significant higher response in patients who received early compared to late vaccination in the chemotherapy cycle was observed. Geometric mean titres post vaccination on day 5 versus day 16 were 69.3 versus 27.4 (H3N2), 76.4 versus 17.5 (H1N1) and 34.4 versus 26.0 (B/Brisbane), respectively. In colorectal cancer patients overall serologic responses were adequate, no significant difference was found between early and late vaccination. Geometric mean titres post vaccination on day 5 versus day 16 were 170.1 versus 192.4 (H3N2), 233.0 versus 280.8 (H1N1) and 62.6 versus 75.9 (B/Brisbane), respectively. Conclusion: Overall antibody response to the influenza virus vaccine in patients treated with chemotherapy for breast or colorectal cancer patients is adequate. Breast cancer patients seem to mount the best antibody response when vaccinated early after a chemotherapy cycle (<= day 5). No difference was found between early and late vaccination in colorectal cancer patients. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码：6177 / 6184
页数：8
相关论文
共 27 条
[1]   Seroconversion after influenza vaccination in patients with lung cancer [J].
Anderson, H ;
Petrie, K ;
Berrisford, C ;
Charlett, A ;
Thatcher, N ;
Zambon, M .
BRITISH JOURNAL OF CANCER, 1999, 80 (1-2) :219-220
[2]  
Arrowood JR, 2002, ANN PHARMACOTHER, V36, P1219
[3]   Humoral immune response after vaccination against influenza in patients with breast cancer [J].
Brydak, LB ;
Guzy, J ;
Starzyk, J ;
Machala, M ;
Gózdz, SS .
SUPPORTIVE CARE IN CANCER, 2001, 9 (01) :65-68
[4]  
Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P521
[5]  
Committee for Proprietary Medicinal Products (CPMP), 1997, CPMPBWP21496
[6]   HARMONIZATION OF REQUIREMENTS FOR INFLUENZA-VIRUS VACCINES - THE FIRST YEARS EXPERIENCE WITH THE EEC GUIDELINE [J].
DAMEN, JEGPC .
BIOLOGICALS, 1993, 21 (02) :179-182
[7]   REACTOGENICITY AND IMMUNOGENICITY OF A SURFACE-ANTIGEN-ADSORBED INFLUENZA-VIRUS VACCINE IN CHILDREN [J].
EASTWOOD, LM ;
JENNINGS, R ;
MILNER, RDG ;
POTTER, CW .
JOURNAL OF CLINICAL PATHOLOGY, 1979, 32 (06) :534-537
[8]  
Fiore Anthony E., 2008, Morbidity and Mortality Weekly Report, V57, P1
[9]   Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible [J].
Gelinck, L. B. S. ;
van den Bemt, B. J. F. ;
Marijt, W. A. F. ;
van der Bijl, A. E. ;
Visser, L. G. ;
Cats, H. A. ;
Rimmelzwaan, G. F. ;
Kroon, F. P. .
VACCINE, 2009, 27 (18) :2469-2474
[10]  
Health Council of the Netherlands, 2007, HLTH COUNC NETH PUBL, V2007/19
123